(Total Views: 806)
Posted On: 01/23/2021 4:16:42 PM
Post# of 154115
Re: Goosebumps #74077
I'm hoping some of our clinical minds can expound on this. Some great data in here
"Leronlimab blocks human CCL5-CCR5-mediated signaling in human breast cancer cells. "
"Leronlimab reduced CCL5-induced calcium responses in MDA-MB-231-CCR5 cells (1.23 ± 0.10, N = 10 for control cells and 0.54 ± 0.13 N = 12 for leronlimab-treated cells. P < 0.001"
"Leronlimab blocks CCR5-mediated invasion of human breast cancer cells into the extracellular matrix
The ability of breast cancer cells to invade extracellular matrix is distinguishable from but an important step in tumor metastasis."
"Leronlimab blocks human CCL5-CCR5-mediated signaling in human breast cancer cells. "
"Leronlimab reduced CCL5-induced calcium responses in MDA-MB-231-CCR5 cells (1.23 ± 0.10, N = 10 for control cells and 0.54 ± 0.13 N = 12 for leronlimab-treated cells. P < 0.001"
"Leronlimab blocks CCR5-mediated invasion of human breast cancer cells into the extracellular matrix
The ability of breast cancer cells to invade extracellular matrix is distinguishable from but an important step in tumor metastasis."
(4)
(0)
